INVA
Innoviva, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.08
+1.44%Oct 19, 2026, 12:00 UTC
Gilead Sciences said it will present 28 research presentations, including two oral presentations, at Innoviva, Inc. 2026 on HIV treatment, prevention, and emerging antiviral programs.
Aug 6, 2026, 01:36 UTC
Innoviva reported Q2 2026 earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share, and compared to $0.77 per share a year ago.
Source:Jun 16, 2026, 12:00 UTC
Innoviva Specialty Therapeutics entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for XACDURO in select international markets.
Source: